Sociodemographic factors predict risk of non-adherence to aromatase inhibitors

Long-term risks from prostate cancer treatment detailed in new report

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

November 08, 2024

Vol.50 No.42

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

November 08, 2024

Vol.50 No.42

Clinical

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.

October 18, 2024

Vol.50 No.39

By McKenzie Prillaman

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

SWOG pilot study confirms feasibility, acceptability of bowel symptom intervention studies

In a pilot study, a telephone-based dietary intervention designed to improve bowel function was shown to be widely acceptable to participants who had had surgery for rectal cancer.

March 15, 2024

Vol.50 No.11

Guest Editorial

SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing

The 2023 San Antonio Breast Cancer Symposium (SABCS), held Dec. 5-9 at the city’s Henry B. Gonzalez Convention Center, had a record-setting attendance with 10,874 registered attendees from 102 countries.

February 16, 2024

Vol.50 No.07

By Virginia Kaklamani, Srivani Ravoori and Carlos L. Arteaga

Sociodemographic factors predict risk of non-adherence to aromatase inhibitors

YOU MAY BE INTERESTED IN

Long-term risks from prostate cancer treatment detailed in new report

Ruxolitinib improves CML’s response to standard TKI treatment

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

Group chairs propose funding strategy to jump-start correlative studies

SWOG pilot study confirms feasibility, acceptability of bowel symptom intervention studies

SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing

Renew today!

Subscriber content

Login

Sociodemographic factors predict risk of non-adherence to aromatase inhibitors

YOU MAY BE INTERESTED IN

Long-term risks from prostate cancer treatment detailed in new report

Ruxolitinib improves CML’s response to standard TKI treatment

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo

Group chairs propose funding strategy to jump-start correlative studies

SWOG pilot study confirms feasibility, acceptability of bowel symptom intervention studies

SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing

Login

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo